Compare 3M Company (MMM) vs Novo Nordisk A/S (NVO) Price & Performance

3M (MMM) trades at $183.58, up 0.85% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding expectations by 6.7%, and raised full-year guidance. Revenue trends show stabilization after 2023 challenges, with 2025 revenue of $24.95B and net income margin of 13.02%. Analyst sentiment is mixed with 48% buy ratings but the stock trades above the consensus price target of $173.

The outlook remains positive with operational improvements and innovation driving growth, particularly in Safety & Industrial and Transportation segments. Key risks include litigation liabilities, macroeconomic headwinds, and valuation concerns with elevated P/E of 32.5. The EBO partnership with Microsoft presents long-term data center growth opportunities, though current pricing may limit near-term upside potential.

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.